Israeli scientists "put to shame" British

Has the final solution to the problem of oncological diseases been found?

Peter Talantov, "Trinity Variant"

A couple of weeks ago, a certain Ilan Morad, the head of a previously unknown Israeli company Accelerated Evolution Biotechnologies Ltd. (AEBi), said that in a year he would achieve no less than a complete cure for cancer. The news spread rapidly, hitting many major media. Those who did not publish it in the early days (honor and praise to them) are tempted to write something about it now. Is it worth doing this?

News in the media is not the best source of information about medicine and medical research. The business model of most media is such that they are more interested in traffic than the correctness and meaningfulness of what is published. To be fair, researchers and drug manufacturers are aggravating the situation by distorting the facts and willingly playing on the love of the media for cheap sensations. The analysis has repeatedly demonstrated that the press releases of scientific groups and the pharmaceutical business tend to embellish the findings and conceal their preliminary nature. Small companies are especially guilty of this – bigpharma, which is under close attention, will not give out unfulfilled promises right and left. Another risk factor is working in areas overheated by the interest of investors and the press, such as cancer.

What's wrong with the Israeli company's statement?

First, according to the press release, AEBi has confirmed the effectiveness of its development in mice and cell cultures. It is probably possible to repeat endlessly that the results obtained on laboratory animals mean practically nothing. And they certainly do not say that a way to treat a disease in a person has been found or will be found. The media is unlikely to ever accept this simple idea – otherwise they would have to drastically reduce the amount of news about the final victories over cancer.

In oncology, a project that has reached the stage of human experiments has about 5% chance of ever becoming a medicine. In our case, there is no question of obtaining permission for clinical trials yet. Probably, the developer is at a fairly early stage of the preclinical search, and in the case of a normal process of creating a drug, the chances would not exceed 2-3%. And taking into account the following oddities, they can be safely reduced by an order of magnitude.

Secondly, the term is ridiculous. Since AEBi has not yet started clinical trials, before the creation of the drug (assuming that it will take place) is not one year, perhaps a dozen years. The drug has not been created until clinical trials have confirmed its effectiveness and safety in humans, and this is a very long process. There is no question of creating a drug "in a year". And those who are engaged in the development of medicines cannot fail to understand this. The chances of fulfilling this promise are zero.

Thirdly, the Israelis claim that they will find treatment not for any of the types of cancer, but from cancer in general. But wait, there is no such disease: there are at least more than a hundred oncological diseases that differ greatly in mechanisms, clinic, course of the disease and, very importantly, treatment methods. We do not know what they have in common that would allow us to create one cure for all types of cancer at once. Most likely because they don't exist. But even if we assume that they exist and Mr. Morad and his colleagues found them - and this is a whole revolution in oncology, pulling several Nobel prizes at once – then where are the publications dedicated to this? It's hard to believe that a small Israeli laboratory could do something that the world pharmaceutical industry could not cope with. And surprisingly, they forgot to stake out their priority. The chances of fulfilling this promise also tend to zero.

Promises to completely solve the cancer problem with one pill are a characteristic sign of fraud. I want to believe that this is not what we are dealing with.

Fourth, there are no traces of the scientific activities of this company in the field of cancer control. Nothing at all. Not a single publication devoted to this method of treatment or previous fundamental research. Neither with the results of animal experiments, nor with experiments on cell cultures. No specifics, just a promise to create a miracle in a year. Moreover, I could not find publications by Ilan Morad and his colleague Dan Aridor at all, clearly related to cancer. Hmm.

Fifth, there is no indication that AEBi is trying to register the drug in the United States or the European Union. Ignoring the main markets is more than strange for a potential mega-blockbuster that could turn the entire global pharmaceutical industry upside down. Isn't the Israeli regulator less demanding? However, nothing is known for sure yet about attempts to register in Israel.

Sixth, as if the above were not enough, Aridor promises no side effects. How can you make such promises before clinical trials? Especially considering that the medicine will be based on a strong toxin?

Seventh, of course, the miracle cure will be very cheap.

So, we have an impossible drug for a non-existent disease, with unexplored efficacy and safety, with incredible properties, which will be manufactured in an unrealistic time by people who are not related to this field of research, who accidentally forgot to publish epoch-making discoveries that preceded the development, pick up their Nobel Prize in between and try to bring the drug to the main markets. If the "Trinity variant" had not asked for a comment on 4-5 thousand characters, I could have limited myself to four: the word "nonsense" completely exhausts the sensation.

Portal "Eternal youth" http://vechnayamolodost.ru